Ceramide derivatives for therapeutic agents

Bibliography

• NISHIZAKA Y: The role of protein kinase C in the cell surface signal transduction and tumour promotion. Nature (1984) 308:693–698.
   PubMedGoogle Scholar
• BERRIDGE MJ, IRVINE RF: Inositol triphosphate, a novel second messenger in cellular signal transduction. Na-ture (1984) 312:315–321.
   PubMed Web of Science ®Google Scholar
• MAJERUS PW, CONNOLLY TM, DECKMYN H et al.: The metabolism of phosphoinositide-derived messenger molecules. Science (1986) 234:1519–1526.
   PubMed Web of Science ®Google Scholar
• LISCOVITCH M: Crosstalk among multiple signal-activated phospholipases. Trends Biochem. Sci. (1992) 17(10)393–399.
   Google Scholar
• IGARASHI Y: Functional roles of sphingosine, sphin-gosine 1-phosphate, and methylsphingosines in re-gard to membrane sphingolipid signaling pathways. J. Biochem. (1997) 122 (6): 1080–1087.
   PubMedGoogle Scholar
• LEE MJ, VAN BROCKLYN JR, THANGADA S et al: Sphingosine- 1 -p hosp hate as a ligand for the G-protein-coupled receptor EDG-1. Science (1998) 279:1552–1555.
   PubMed Web of Science ®Google Scholar
• •First report of the cell surface receptor for sphingosine derivatives.
   Google Scholar
• VAN BROCKLYN JR, LEE MJ, MENZELEEV R et al: Dual ac-tions of sphingosine-1 -phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellu-lar to regulate proliferation and survival. J. Cell Biol. (1998) 142(0:229–240.
   PubMedGoogle Scholar
• SWEENEY EA, SAKAKURA C, SHIRAHAMA T et al.: Sphin-gosine and /V,/V-dimethylsphingosine induce apopto-sis in a variety of human cancer cell lines. Int. J. Cancer (1996) 66(3):358–366.
   PubMedGoogle Scholar
• SAKAKURA C, SWEENEY EA, SHIRAHAMA T et al: Inhibi-tion of MAP kinase by sphingosine and its methylated derivative /V,/V-dimethylsphingosine; a correlation with induction of apoptosis in solid tumor cells. Int. J. Oncol. (1997) 11(0:31–39.
   PubMedGoogle Scholar
• SHIRAHAMA T, SWEENEY EA, SAKAKURA C et al: In vitroand in vivo induction of apoptosis by sphingosine and /V,/V-dimethylsphingosine in human epidermal carci-noma KB-3-1 and its multidrug resistant cells. Clin. Cancer Res. (1997) 3(2):257–264.
   PubMedGoogle Scholar
• MUROHARA T, BUERKE M, MARGIOTTA J et al.: Myocar-dial and endothelial protection by /V,/V,/V-trimet-hylsphingosine in feline myocardial ischemia and reperfusion injury. Am. J. Physiol. (1995) 269(Heart Circ. Physiol. 38) :H504–514.
   Google Scholar
• SCALIA R, MUROHARA T, DELYANI JA, NOSSULI 0, LEFERAM: Myocardial protection by /V,/V,/V-trimethylsphi-ngosine in ischemia reperfusion injury is mediated by inhibition of P-selectin. j Leukoc. Biol. (1996) 59(3):317–324.
   PubMedGoogle Scholar
• NATORI T, KOEZUKA Y, HIGA T: Agelasphins, novel a-galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett. (1993) 34(35):5591–5592.
   Google Scholar
• •First report of a-galactosylceramides from marine sponge that have antitumour activity.
   Google Scholar
• NATORI T, MORITA M, AKIMOTO K, KOEZUKA Y: Agelas-phins, novel antitumor and immunmostimulatory cerebrosides from the marine sponge Agelas mauri-tianus. Tetrahedron (1993) 50(9):2271–2784.
   Google Scholar
• KAWANO T, CUI J, KOEZUKA Y et al: CD1d-restrictedand TCR-mediated activation of Va14 NKT cells by gly-cosylceramides. Science (1997) 278: 1626-1629.
   Google Scholar
• •First report of the unique immunostimulatory mechanism of the a-galactosylceramide.
   Google Scholar
• HANNUN YA: The sphingomyelin cycles and the sec-ond messenger function of ceramide. J. Biol. Chem. (1994) 269(5):3125–3128.
   PubMed Web of Science ®Google Scholar
• PUSHKAREVA M, OBEID LM, HANNUN YA: Ceramide: anendogenous regulator of apoptosis and growth sup-pression. Immunol. Today (1995) 16(6):294–297.
   PubMedGoogle Scholar
• SCHWARTZ GK, WARD D, SALTZ L et al.: A pilot clini-cal/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res. (1997) 3(4)537–543.
   Google Scholar
• MANDALA SM, THORNTON R, TU Z etal.: Sphingoid base1-phosphate phosphatase: a key regulator of sphin-golipid metabolism and stress response. Proc. Natl. Acad. Sci. USA (1998) 95(0:150–155.
   Google Scholar
• CUVILLIER 0, PIRIANOV G, KLEUSER B et al.: Suppres-sion of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature (1996) 381:800–803.
   Google Scholar
• SUN L, XU L, HENRY FA, SPIEGEL S, NIELSEN TB: A newwound healing agent: sphingosylphosphorylcholine. J. Invest. Dermatol. (1996) 106(2):232–237.
   PubMedGoogle Scholar
• TODDERUD G, NAIR X, LEE D etal: BMS-190394, selectininhibitor, prevents rat cutaneous inflammatory reac-tions. J. Pharmacol. Exp. Ther. (1997) 282(3):1298–1304.
   PubMedGoogle Scholar
• AKIMOTO K, NATORI T, MORITA M: Synthesis and stereochemistry of Agelasphin-9b. Tetrahedron Lett. (1993) 34(35):5593–5596.
   Google Scholar
• MORITA M, MOTOKI K, AKIMOTO K et al: Structure- activity relationship of a-galactosylceramides against B16-bearing mice. J. Med. Chem. (1995) 38(12)2176–2187.
   Google Scholar
• •This article discusses the chemistry and structure antitumour activity relationship of a-galactosylceramides.
   Google Scholar
• HOSHI A, CASTANER J: KRN-7000. Drugs Future (1996) 21(2):152–154.
   Google Scholar
• Drugs Future (1997) 22(2):185–187.
   Google Scholar
• MOTOKI K, KOBAYASHI E, MORITA M et al: Effects of a a-galactosylceramide on bone marrow cells in vitro and hematopoiesis in vivo. Biol. Pharm. Bull. (1996) 19(7)952–955.
   Google Scholar
• MOTOKI K, MORITA M, KOBAYASHI E et al.: Radiopro-tective effects of a-galactosylceramides. Bioorg. Med. Chem. Lett (1996) 5(20):2413–2416.
   Google Scholar
• MOTOKI K, MAEDA K, UENO H et al.: Antitumor activi-ties of combined treatment with a novel immuno-mo dulator, (25,35,4R)-1-0-(a-D-galactopyranosy0-2-(N-Hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice. Oncol. Res. (1996) 8(4):155–162.
   PubMedGoogle Scholar
• YAMAGUCHI Y, MOTOKI K, UENO H et al: Enhancing ef-fects of (25,35,4R)-1-0-(a-o-galactopyranosy0-2-(N- hex aco s anoylamino) -1, 3,4 - o ctade c anet ri ol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. (1996) 8(10/10:399–407.
   Google Scholar
• PAGLIA P, BEISSERT S, SCHWARTZ T, GRANSTEIN RD: Murine dendritic cells loaded in vitro with soluble pro-tein prime toxic T lymphocytes against tumor antigen in vivo. J. Exp. Merl. (1996) 183(1):317–322.
   PubMed Web of Science ®Google Scholar
• CELLUZZI CM, MAYORDOMO JI, STORKUS WJ, LOTZE MT, FALO LD, Jr.: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor im-munity. J. Exp. Med. (1996) 183(1):283–287.
   Google Scholar
• CONSTANTINO V, FATTORUSSO E, MANGONI A, AKNIN M, GAYDOU EM: Axiceramide A and B, two novel tri-a-glycosylceramides from the marine sponge Axi- nella sp. Liebigs Ann. Chem. (1994) (12) :1181–1185.
   Google Scholar
• CAFIERI F, FATTORUSSO E, MAHAJNAH Y, MANGONI A: Longiside, a novel digalactosylceramide from the Car-ibbean sponge Agelas longissima. Liebigs Ann. Chem. (1994) (12):1187–1189.
   Google Scholar
• CAFIERI F, FATTORUSSO E, MANGONI A, TAGLI ALATELA-SCAFATI 0: Glycosyl ceramide composition of the marine sponge Agelas longissima. Liebigs Ann. Chem. (1995) 1995 (8):1477–1481.
   Google Scholar
• CONSTANTINO V, FATTORUSSO E, MANGONI A et al. Glycolipids from sponges. IV. Immunomodulating gly-cosyl ceramides from the marine sponge Agelas dis-par. Tetrahedron (1996) 52(5):1573–1578.
   Google Scholar
• UCHIMURA A, SHIMIZU T, NAKAJIMA M et al.: Immu-nostimulatory activities of mono- or diglycosylated a-galactosylceramides. Bioorg. Med. Chem. (1997) 5(7):1447–1452.
   PubMedGoogle Scholar
• BOYD B, MAGNUSSON G, ZIUYAN Z, LINGWOOD CA: Lipid modulation of glycolipid receptor function. Eur. Biochem (1994) 223:873–878.
   PubMedGoogle Scholar
• VANMIDDLESWORTH Y, GIACOBBE RA, LOPEZ M et al.: Sphingofungines A, B, C, and D; A new family of anti-fungal agents. J. Antibiol (1992) 45 (6):861–867.
   PubMed Web of Science ®Google Scholar
• FUJITA T, INOUE K, YAMAMOTO S et al.: Fungal metabo-lites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. AntibioL (1994) 47 (2):208–215.
   Google Scholar
• FUJITA T, YONETA M, HIROSE R et al.: Simple com-pounds, 2-alkyl-2-amino-1,3-propanediols have po-tent immunosuppressive activity. Bioorg. Med. Chem. Lett. (1995) 5(8):847–852.
   Google Scholar
• ADACHI K, KOHARA T, NAKAO N et al.: Design, synthe-sis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. (1995) 5(8):853–856.
   Web of Science ®Google Scholar
• •This article shows the structure immunosuppressive activity relationship of ISP-I to obtain a simplified attractive compound.
   Google Scholar
• NAKAGAWA R, MOTOKI K, UENO H et al.: Treatment of hepatic metastasis of the colon26 adenocarcinoma with an a-galactosylceramide, KRN7000. Cancer Res. (1998) 58(9):1202–1207.
   PubMedGoogle Scholar
• SPADA F, KOEZUKA Y, PORCELLI SA: CD1d-restricted recognition of synthetic glycolipid antigens by human NK T cells. J. Exp. Med. (1998) 188(8):1529–1534.
   PubMed Web of Science ®Google Scholar
• BROSSAY L, CHIODA M, BURDIN N et al.: CD id-mediated recognition of an a-galactosylceramide by natural kil-ler T cells is highly conserved through mammalian evolution. J. Exp. Med. (1998) 188(8):1521–1528.
   PubMedGoogle Scholar